Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that its Board of Directors is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE